UBI is a privately held multinational biopharmaceutical company dedicated to the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases.
Our product pipeline is filled with our new line of synthetic peptide-based biologicals for the treatment and prevention of Alzheimer’s Disease, AIDS, Autoimmune diseases, and Allergy, along with a portfolio of Animal health diseases. These products are based on our proprietary designer peptides, vaccine formulation systems, and methods to manufacture therapeutic monoclonal antibodies.
Our platform technologies from molecular and cellular engineering of high yield antibody and protein production of specific products by CHO cells are also being used to develop a line of biosimilar and biobetter versions of widely used protein and antibody drugs whose patents are about to expire.
UBI’s proprietary designer peptide technology has been used to produce a line of blood screening diagnostics and the first successfully commercialized synthetic peptide vaccine. A second designer peptdie vaccine for immunocastration has gained product regulatory approvals as first class new biologics in Taiwan, Mexico and Brazil with many more to follow.
Additional revenue streams are generated from pharmaceutical contract manufacturing by our subsidiary UBI-Asia and various sponsorships in product development.